Clarus Therapeutics Holdings, Inc. - POS AM filing on 2022-04-01

Stock Based Compensation (Tables)

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Schedule of weighted-average assumptions

The key assumptions used to apply this pricing model were as follows:


	Year Ended December 31,
	2021
Risk free interest rate		1.34	%
Expected term (in years)		5.95
Expected dividend yield		0	%
Expected volatility of underlying common stock		79.76	%

Schedule of stock option activity under the Plans

The following table summarizes the stock option activity under the 2021 Plan:


	Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)		Intrinsic Value (in thousands)
Outstanding January 1, 2021		—	$	—		—	$	—
Granted		1,083,550		4.78		9.95
Exercised		—
Canceled		—

Outstanding December 31, 2021		1,083,550	$	4.78		9.95	$	—

Options vested or expected to vest as of December 31, 2021		—	$	—		—	$	—

Stock options unvested as of December 31, 2021		1,083,550	$	4.78		9.95	$	—

Summary of Restricted Common Stock Activity

A summary of the activity for the year ended December 31, 2021 is as follows:


	Number of Shares		Weighted Average Grant Date Fair Value
Unvested restricted stock as of January 1, 2021		—	$	—
Granted		433,420	$	4.78

Unvested restricted stock as of December 31, 2021		433,420	$	4.78

Schedule of stock-based compensation expense

Stock-based compensation expense, including expense associated with the Legacy Clarus incentive plans up until the date of the business combination ($559 in 2021 and $825 in 2020), is as follows (in thousands):


	Years Ended December 31,
	2021		2020
Selling and marketing	$	43	$	183
Research and development		60		189
General and administrative		565		453

Total stock-based compensation expense	$	668	$	825